Advances of programmed death ligand 1 and its inhibitor in non-small cell lung cancer
103760/cma.j.issn.1673-422X.201508.019
- VernacularTitle:程序性死亡配体-1及其抑制剂在非小细胞肺癌中的研究进展
- Author:
Rui GENG
;
Li PAN
;
Xia SONG
- Publication Type:Journal Article
- Keywords:
Carcinoma,nonsmall cell lung;
Immunosuppressive agents;
Programmed death ligand 1
- From:
Journal of International Oncology
2015;(8):628-630
- CountryChina
- Language:Chinese
-
Abstract:
Programmed death-ligand 1 (PD-L1 ),which is highly expressed in NSCLC,can be divided into two categories:membrane PD-L1 and soluble PD-L1 .PD-L1 participates in tumor immune escape through combining with its receptor.PD-L1 immune checkpoint inhibitors have entered the phase Ⅰ studies and showed a good application prospect.It is also found that the sensitivity of PD-L1 immune checkpoint inhibitors is strongly associated with the expression of PD-L1 in tumor.Therefore,PD-L1 can be used as a biomarker to pre-dict its curative effect.
